HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Isocarboxazid

HCID 3759
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
59-63-2
Standard SMILES
Cc1cc(C(=O)NNCc2ccccc2)no1
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
Molecular formula
C12H13N3O2
Average molar mass
231.25 g/mol
Monoisotopic mass
231.10077667

Overview

5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide is a member of benzenes.

Names & identifiers

Preferred name
Isocarboxazid
IUPAC
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
English name
ISOCARBOXAZID (200 MG)
Molecular formula
C12H13N3O2
Molecular weight
231.25

Names & synonyms

isocarboxazid59-63-2IsocarboxazideEnerzerMarplanIsocarbonazidIsocarbossazideN'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazideIsocarboxazidaRo 5-0831Isocarboxazidum5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide
Show more names
1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazineBmihMarplonBenazideMaraplanro5-0831
3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazideDTXSID4023171NSC-169893RO-5-0831NSC169893DTXCID00317134237V843T4-27-00-03999 (Beilstein Handbook Reference)

Database identifiers

CAS
59-63-2
PubChem CID
3759
DTXSID
DTXSID4023171
ChEMBL
CHEMBL1201168
ChEBI
CHEBI:93635
UNII
34237V843T
EC Number
200-438-4
Nikkaji
J4.794E

Properties

Computed structural propertiesFilling in

XLogP
1.5
Topological polar surface area
67.2 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
4
Rotatable bonds
4
Heavy atoms
17
Formal charge
0
Complexity
254

Experimental & physicochemical properties

Drugs · 2 items

DEA NFLIS-Drug Category -> Stimulants

Pharmaceuticals -> Listed in ZINC15

LogP · 2 items

2.4

1.49

Solubility · 2 items

Very slightly soluble in hot water

2.24e-01 g/L

Human Drugs · 5 items

Antidepressants -> Monoamine oxidase inhibitors (MAOI)

Breast Feeding; Lactation; Antidepressive Agents; Monoamine Oxidase Inhibitors;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling Point394.5ºC at 760 mmHg
Melting Point · 2 items

105-106 °C

105 - 106 °C

Physical DescriptionSolid
Dissociation Constants10.4

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.

Hazard information

Regulatory Information3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxicology

Treatment · 1 item

General supportive measures should be used, along with immediate gastric lavage or emetics. If the latter are given, the danger of aspiration must be borne in mind. An adequate airway should be maintained, with supplemental oxygen if necessary. The mechanism by which amine-oxidase inhibitors produce hypotension is not fully understood, but there is evidence that these agents block the vascular bed response. Thus it is suggested that plasma may be of value in the management of this hypotension. Administration of pressor amines such as levarterenol bitartrate may be of limited value (note that their effects may be potentiated by Isocarboxazid). Continue treatment for several days until homeostasis is restored. Liver function studies are recommended during the 4 to 6 weeks after recovery, as well as the time of overdosage.

Hepatotoxicity · 1 item

Isocarboxazid, like most monoamine oxidase (MAO) inhibitors, can cause transient serum aminotransferase elevations in a proportion of patients. These elevations are usually mild, asymptomatic and self-limited and do not require dose modification. MAO inhibitors have been associated with rare cases of acute, clinically apparent liver injury but isocarboxazid has not specifically been implicated. The time to clinical onset of liver injury due to MAO inhibitors is typically 1 to 4 months after starting and the usual pattern of serum enzyme elevations is hepatocellular, although cholestatic injury has also been described. Immunoallergic features (rash, fever, eosinophilia) are uncommon as is autoantibody formation. Isocarboxazid has not been directly implicated in cases of drug-induced liver injury but it has had limited clinical use.

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein Binding · 1 item

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs present a very high protein binding percentage.

Pharmacodynamics · 1 item

In vivo and in vitro studies demonstrated isocarboxazid-driven inhibition of MAO in the brain, heart, and liver. The reduced MAO activity, caused by isocarboxazid, results in an increased concentration of serotonin, epinephrine, norepinephrine, and dopamine in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. The increase of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors like isocarboxazid.

Mechanism of Action · 1 item

Isocarboxazid works by irreversibly blocking the action of monoamine oxidases (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). Isocarboxacid, like other monoamine oxidase inhibitors, are unique psychopharmacological agents whose clinical effect is related to the direct action of the monoamine oxidases to transform them into reactive metabolites.

Biological Half-Life · 1 item

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor. These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.

Metabolism/Metabolites · 2 items

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are rapidly metabolized by acetylation in the liver. As part of the metabolism, hippuric acid is a major metabolite.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Collision Cross Section · 2 items

150.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

152.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

Melting point
98 · 98-1000C
Boiling point
373.33 °C · 373.33°C (rough estimate)
Density
1.206 · 1.206
refractive index
1.529 · 1.5290 (estimate)
storage temp.
-20 °C · -20°C Freezer
solubility
Acetonitrile: Slightly Soluble; Chloroform: Slightly Soluble
form
A solid
pka
10.4 · pKa 10.4 (Uncertain)
color
White to off-white
Water Solubility
0.8 g/L · 0.8g/L(25 ºC)
InChI
1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
SMILES
Cc1cc(no1)C(=O)NNCc2ccccc2
EWG's Food Scores
1 · 1
FDA UNII
34237 V843T · 34237V843T
ATC code
6 AF01 · N06AF01
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301
Precautionary statements
264 · P264-P270-P301+P310-P405-P501
RIDADR
3249 · 3249
WGK Germany
3 · WGK 3
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2934990002 · 2934990002
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 Oral · Acute Tox. 3 Oral
Exposure RoutesWell absorbed from the gastrointestinal tract.
Toxicity Summary · 1 item

Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

Signs and Symptoms · 1 item

Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Isocarboxazid

Ambiguous-DILI-concern

5

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
WGK 3
ridadr
3249
hs_code
2934990002
Signal word
Danger
Symbol(GHS)
GHS06
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301
Hazard Classifications
Acute Tox. 3 Oral
Precautionary statements
P264-P270-P301+P310-P405-P501

Hepatic and rapid (by oxidation).

FDA Pharmacological Classification · 6 items

34237V843T

ISOCARBOXAZID

Established Pharmacologic Class [EPC] - Monoamine Oxidase Inhibitor

Mechanisms of Action [MoA] - Monoamine Oxidase Inhibitors

Isocarboxazid is a Monoamine Oxidase Inhibitor. The mechanism of action of isocarboxazid is as a Monoamine Oxidase Inhibitor.

ISOCARBOXAZID

MeSH Pharmacological Classification · 2 items

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Absorption, Distribution and Excretion · 2 items

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.

Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours. From this amount, 75% of the renally eliminated drug is in the form of hippuric acid. Another section of the eliminated dose is observed through the intestinal tract and it accounts for 22% of the administered dose after 24 hours.

Cellular LocationsCytoplasm

Uses & manufacturing

UsesMay be used to treat major depressive disorder.
Use ClassificationPharmaceuticals

Applications

UsesIsocarboxazid is a powerful MAO inhibitor. As with phenelzine, isocarboxazid is used for depressions that do not respond to other drugs.

UsesMonoamine oxidase inhibitor. Antidepressant

Upstream & downstream products

Upstream raw materials

Lithium Aluminum HydrideBenzaldehyde5-Methyl-3-isoxazolecarboxylic Acid HydrazideBenzylhydrazine dihydrochloride5-Methyl-3-isoxazolecarboxylic Acid BenzylidenehydrazideMethyl 5-methylisoxazole-3-carboxylateBenzylhydrazine

Additional notes

DefinitionChEBI: 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide is a member of benzenes.